Pharma and Biotech
Period Ending | Period | Revenue (£m) | Pre-tax (£m) | EPS | Dividend |
---|---|---|---|---|---|
30-Jun-24 | Interim | n/a | (0.47) | (0.38)p | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 0.52 | (0.45) | (0.65)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 0.22 | (0.95) | (1.36)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 0.54 | (2.70) | (2.61)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | 0.59 | (3.12) | (3.00)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Forecasts data is not available for this company.
Copyright © 2024 FactSet Research Systems Inc. All rights reserved.
5 Yr High | 5 Yr Low | 5 Yr Avg | Curr / Avg | |
---|---|---|---|---|
Latest | n/a | n/a | n/a | 0 |
Find out about IFRS and how this affects the financial infomation for all UK companies.
Currency | UK Pounds |
Share Price | 0.20p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 1.30p |
52 Week Low | 0.12p |
Volume | 0 |
Shares Issued | 2,295.93m |
Market Cap | £4.48m |
Beta | 0.81 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
CEO | Anthony Tennyson |
Chair | Dennis Purcell |
You are here: research